Kiyoko Oshima

Johns Hopkins University — United States

Medicine · Health Sciences

29h-index2.4kcitations150works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(28), Liver Disease Diagnosis and Treatment(22), Radiomics and Machine Learning in Medical Imaging(19), Cholangiocarcinoma and Gallbladder Cancer Studies(15), Gastric Cancer Management and Outcomes(11)

Publications150 total

Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development
npj Precision Oncology·2025· 1 citedOpen Access
Liver tumors associated with congenital portosystemic shunts – report of 3 cases and literature review
Abdominal Radiology·2025
Pulse Granuloma-Like Lesion of the Portal Vein in a Liver Explant: A Case Supporting the Endogenous Theory
Cureus·2025Open Access
[Development of Immunotherapy to Target Autophagy‒Dependent Immune Evasion in Pancreatic Cancer].
PubMed·2025
Pilomatrix carcinoma-like gallbladder carcinoma
Human Pathology Reports·2025Open Access
Can We Define a High‐Grade Precursor of Small Duct Intrahepatic Cholangiocarcinoma?
Pathology International·2025Open Access
Prenatal diagnosis of umbilical–portal–systemic venous shunt associated with gestational alloimmune liver disease
Ultrasound in Obstetrics and Gynecology·2025· 1 citedOpen Access
Abstract 5071: Spatially resolved gene expression analysis of primary and metastatic fibrolamellar hepatocellular carcinoma (FLC)
Cancer Research·2025· 1 cited
Propensity score–weighted analysis of neoadjuvant therapy versus upfront surgical resection in patients with biliary tract cancers
Surgical Oncology Insight·2025Open Access
Cholangioblastic Cholangiocarcinoma (NIPBL::NACC1 Cholangiocarcinoma)
The American Journal of Surgical Pathology·2025· 3 cited
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma
Hepatology·2024· 7 citedOpen Access
Supplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
2024Open Access
Supplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
2024Open Access
Supplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
2024Open Access
Table 2 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
2024Open Access
Supplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
2024Open Access
Data from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
2024Open Access
Table 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
2024Open Access
Table 3 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
2024Open Access
Table 3 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC
2024Open Access
page 1 of 8Next →

Frequent Co-authors

Yi‐Wen Huang(16), Li-Shu Wang(15), Pan Pan(13), Martha Yearsley(13), Jianhua Yu(13), Gary D. Stoner(7), Jianying Zhang(5), Hsin‐Tzu Wang(5), Susan Tsai(5), Chieh-Ti Kuo(4), Li‐Shu Wang(4), Bradley A. Erickson(4), Mark Arnold(4), Barbara Ulmasov(4), Chad W. Skaer(4), Seung‐Mo Hong(3), Daniel S. Peiffer(3), William A. Hall(3), X. Allen Li(3), Jianying Zhang(3)